



CVS Health Corporation (CVS)

Updated May 4th, 2021 by Nathan Parsh

Key Metrics

Current Price:	\$80	5 Year CAGR Estimate:	8.2%	Market Cap:	\$104 billion
Fair Value Price:	\$84	5 Year Growth Estimate:	5.0%	Ex-Dividend Date:	7/22/2021 ¹
% Fair Value:	95%	5 Year Valuation Multiple Estimate:	0.9%	Dividend Payment Date:	8/34/2021 ²
Dividend Yield:	2.5%	5 Year Price Target	\$107	Years Of Dividend Growth:	0
Dividend Risk Score:	B	Retirement Suitability Score:	B	Last Dividend Increase:	17.6% (2017)

Overview & Current Events

CVS Health Corporation is an integrated healthcare services provider that operates a pharmaceutical services business, along with the country's largest chain of pharmacies. The company operates more than 9,900 retail locations, 1,100 medical clinics, and services more than 102 million plan members. CVS Health Corporation generates annual revenues of about \$280 billion. On 11/11/18, CVS Health Corporation completed its acquisition of Aetna. The company achieved more than \$900 million in cost synergies related to the acquisition in 2020, above its target of \$750 million.

CVS Health Corporation announced first quarter earnings results on 5/04/2021. For the quarter, revenue increased 3.5% to \$69.1 billion, beating estimates by \$750 million. Adjusted earnings-per-share of \$2.04 grew 6.8% from the prior year and was \$0.32 better than expected.

Pharmacy Services was higher by 3.8% even as total pharmacy claims processed fell 1%. Specialty Pharmacy remains strong as revenue was up 7.2% due to new business and brand inflation. Revenues for the Retail/LTC segment grew 2.3%. Prescriptions filled inched higher by 0.1%. Cold, cough and flu sales remain challenged due to social distancing restrictions related to COVID-19. Retail pharmacy same store sales were up 0.4% as a 4.1% increase in pharmacy sales and a 1% gain in pharmacy volumes were nearly offset by a 11.4% decline in front of store sales. The decline in front of store sales is not surprising given the advanced purchasing done ahead of the pandemic last year. Weaker cold, cough and flu also impacted results for this segment. Retail pharmacy script share improved 40 basis points to 26.2%. Revenues for Health Care Benefit increased 6.7%. Government memberships remain strong, growing 15.3% year-over-year which offset a 4.5% decrease in commercial memberships. Cash from operations declined 12.5% to \$2.9 billion. The company also repaid \$3 billion of net debt and remains on track to achieving its target of low 3x leverage in 2022. CVS Health Corp stated that they had vaccinated nearly 6.5 million people through the end of April and that approximately 9% of those vaccinated also filled their first prescription at a store location.

CVS Health Corp updated guidance for 2021 as well. The company expects adjusted earnings-per-share of \$7.56 to \$7.68, up from a range of \$7.39 to \$7.55 previously. We have updated our estimates for the year accordingly.

Growth on a Per-Share Basis

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2026
EPS	\$2.80	\$3.43	\$4.00	\$4.51	\$5.16	\$5.84	\$5.90	\$7.08	\$7.08	\$7.50	\$7.62	\$9.73
DPS	\$0.50	\$0.65	\$0.90	\$1.10	\$1.40	\$1.70	\$2.00	\$2.00	\$2.00	\$2.00	\$2.00	\$2.55
Shares³	1298	1231	1180	1140	1101	1061	1014	1126	1301	1311	1322	1275

CVS Health Corporation's historical growth has been remarkable. The company has compounded its earnings and dividends at annualized rates of 11.6% and 16.7%, respectively, over the last decade. The dividend growth rate is especially impressive given that the company has frozen its dividend for the past four years. The acquisition of Aetna, which had nearly 40 million members at the time of purchase, offered CVS Health Corporation a significant increase in

¹ Estimated ex-dividend date

² Estimated date

³ In millions of shares

Disclosure: This analyst has a long position in the security discussed in this research report.



CVS Health Corporation (CVS)

Updated May 4th, 2021 by Nathan Parsh

the number of potential customers. It is also a positive that the company was able to pay down a sizeable amount of debt in recent quarters. We are forecasting 5% earnings-per-share growth for CVS over the medium term due to revenue increases and cost synergies from the Aetna transaction. Dividend growth during this time period is likely to underwhelm as CVS has frozen its dividend, instead focusing on reducing debt.

Valuation Analysis

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Now	2026
Avg. P/E	12.9	13.2	14.7	17.4	19.7	15.9	13.2	10.0	8.7	8.5	10.5	11.0
Avg. Yld.	1.4%	1.4%	1.5%	1.4%	1.4%	1.8%	2.6%	2.8%	3.3%	3.3%	2.5%	2.4%

Shares of CVS Health Corporation have increased \$8, or 11.1%, since our 2/17/2021 report. Using the midpoint of the company's updated guidance for 2021, the stock is trading at a price-to-earnings ratio of 10.5, which compares favorably to its 10-year average of 13.4. We maintain our 2026 target P/E of 11. Our target P/E might be increased if CVS Health Corporation continues to show strong growth rates. Still, if our current target valuation is achieved, investors would see an additional 0.9% added to annual returns through 2026.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2026
Payout	18%	19%	23%	24%	27%	29%	34%	28%	28%	27%	26%	26%

CVS Health Corporation's most compelling competitive advantage is its entrenched position in the pharmaceutical retail industry. The industry is highly regulated, which makes it difficult for new competitors to enter into the industry and gain market share. In addition, the company is one of the largest pharmacies in the United States (along with Walgreens Boots Alliance), which allows it to capture economies of scale and pressure its suppliers into delivering better prices. CVS Health Corp controlled 26.2% of the retail pharmacy market share as of the end of the first quarter of 2021.

Final Thoughts & Recommendation

Following first quarter earnings results, CVS Health Corporation is projected to offer an annual return of 8.2% through 2026, down from 10.1% previously. Our estimate stems from a 5% annual earnings growth rate, 2.5% starting yield and a slight contribution from multiple expansion. The company turned in a solid first quarter as most areas of the business showed growth. CVS Health Corporation continues to enjoy a strong market share for prescriptions and successfully converted COVID-19 vaccine recipients into new customers at a high rate. We have raised our 2026 price target \$1 to \$107 due to projected returns, but view shares as a hold due to projected returns. We would be buyers of the stock on a pullback.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has a long position in the security discussed in this research report.



CVS Health Corporation (CVS)

Updated May 4th, 2021 by Nathan Parsh

Income Statement Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Revenue (\$B)	107,080	123,120	126,761	139,367	153,290	177,546	184,786	194,579	256,776	268,706
Gross Profit	20,562	22,488	23,783	25,367	26,528	28,834	28,528	31,538	45,528	49,046
Gross Margin	19.2%	18.3%	18.8%	18.2%	17.3%	16.2%	15.4%	16.2%	17.7%	18.3%
D&A Exp.	1,568	1,753	1,870	1,931	2,092	2,475	2,479	2,718	4,371	4,441
Operating Profit	6,331	7,210	8,037	8,799	9,475	10,386	9,719	10,170	11,987	13,911
Op. Margin	5.9%	5.9%	6.3%	6.3%	6.2%	5.8%	5.3%	5.2%	4.7%	5.2%
Net Profit	3,462	3,864	4,592	4,644	5,237	5,317	6,622	(594)	6,634	7,179
Net Margin	3.2%	3.1%	3.6%	3.3%	3.4%	3.0%	3.6%	-0.3%	2.6%	2.7%
Free Cash Flow	3,984	4,641	3,799	6,001	6,172	7,917	6,089	6,828	10,391	13,428
Income Tax	2,258	2,436	2,928	3,033	3,386	3,317	1,637	2,002	2,366	2,569

Balance Sheet Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total Assets	64,543	66,221	71,526	74,187	92,437	94,462	95,131	196,456	222,449	230,715
Cash & Equivalents	1,413	1,375	4,089	2,481	2,459	3,371	1,696	4,059	5,683	7,854
Acc. Receivable	6,047	6,479	8,729	9,687	11,888	12,164	7,895	6,497	6,717	7,101
Inventories	10,046	11,032	11,045	11,930	14,001	14,760	15,296	16,450	17,516	18,496
Goodwill & Int.	36,327	36,148	36,071	37,916	51,984	51,760	52,081	115,202	112,870	110,694
Total Liabilities	26,492	28,568	33,588	36,224	55,234	57,628	57,436	137,913	158,279	161,014
Accounts Payable	4,370	5,070	5,548	6,547	7,490	7,946	8,863	8,925	10,492	11,138
Long-Term Debt	10,014	9,828	13,402	12,890	27,464	27,531	27,002	73,429	68,480	64,647
Total Equity	38,051	37,653	37,938	37,958	37,196	36,830	37,691	58,225	63,864	69,389
D/E Ratio	0.26	0.26	0.35	0.34	0.74	0.75	0.72	1.26	1.07	0.93

Profitability & Per Share Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Return on Assets	5.5%	5.9%	6.7%	6.4%	6.3%	5.7%	7.0%	-0.4%	3.2%	3.2%
Return on Equity	9.1%	10.2%	12.1%	12.2%	13.9%	14.4%	17.8%	-1.2%	10.9%	10.8%
ROIC	7.2%	8.1%	9.3%	9.1%	9.1%	8.2%	10.3%	-0.6%	5.0%	5.4%
Shares Out.	1298	1231	1180	1140	1101	1061	1014	1126	1301	1311
Revenue/Share	79.50	96.19	103.39	119.22	136.14	164.55	180.46	186.38	196.76	204.49
FCF/Share	2.96	3.63	3.10	5.13	5.48	7.34	5.95	6.54	7.96	10.22

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.